Advertisement

Reply to: “B vitamins for NASH: Use methylcobalamin, not cyanocobalamin”

  • Madhulika Tripathi
    Correspondence
    Corresponding authors. Address: Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, 8 College Road, 169857, Singapore. Telephone: (+65) 65166719; Fax (+65) 62212534 (P.M. Yen).
    Affiliations
    Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, 169857, Singapore
    Search for articles by this author
  • Brijesh Kumar Singh
    Affiliations
    Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, 169857, Singapore
    Search for articles by this author
  • Paul Michael Yen
    Correspondence
    Corresponding authors. Address: Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders Program, Duke-NUS Medical School, 8 College Road, 169857, Singapore. Telephone: (+65) 65166719; Fax (+65) 62212534 (P.M. Yen).
    Affiliations
    Laboratory of Hormonal Regulation, Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, 169857, Singapore

    Duke Molecular Physiology Institute, Duke University School of Medicine, 300 N Duke St, Durham, NC 27701, USA

    Endocrinology, Metabolism, and Nutrition, 30 Duke Medicine Circle Clinic 1A, Durham, NC 27710, United States
    Search for articles by this author
Published:October 14, 2022DOI:https://doi.org/10.1016/j.jhep.2022.10.004
      We appreciate the letter by Dr. Spence advocating the use of methylcobalamin or hydroxycobalamin rather than the cyanocobalamin form of vitamin B12 (B12) in future clinical trials investigating the efficacy of B vitamins to prevent or treat NASH.

      Spence JD, B vitamins for NASH: use methylcobalamin, not cyanocobalamin, J Hepatol2023;78:e34–e35 https://dx.doi.org/10.1016/j.jhep.2022.08.019

      This is similar to the concern that he raised previously regarding studies that employed B12 for the prevention of stroke.
      • Spence J.D.
      • Hankey G.J.
      Problem in the recent American heart association guideline on secondary stroke prevention: B vitamins to lower homocysteine do prevent stroke.
      ,
      • Saposnik Gustavo
      The role of vitamin B in stroke prevention. A journey from observational studies to clinical trials and critique of the VITAmins to prevent stroke (vitatops).
      Although several large trials previously showed no benefit of folate and/or B vitamins (B6 and B12) in reducing cardiovascular events,
      • Saposnik Gustavo
      The role of vitamin B in stroke prevention. A journey from observational studies to clinical trials and critique of the VITAmins to prevent stroke (vitatops).
      reanalysis of data from one of them (the VISP trial) showed there was a 34% reduction in stroke/myocardial infarction events over 2 years when patients with impaired renal function were excluded.
      • Spence J.D.
      • Bang H.
      • Chambless L.E.
      • Stampfer M.J.
      Vitamin intervention for stroke prevention trial: an efficacy analysis.
      Subsequent studies using folate supplementation of enalapril in the China Stroke Primary Prevention trial and folate, B6, and low dose B12 in the Su.Fol.M3 trial also showed beneficial stroke prevention effects.
      • Xu X.
      • Qin X.
      • Li Y.
      • Sun D.
      • Wang J.
      • Liang M.
      • et al.
      Efficacy of folic acid therapy on the progression of chronic kidney disease: the renal sub study of the China stroke primary prevention trial.
      ,
      • Galan Pilar
      • Kesse-Guyot Emmanuelle
      • Czernichow Sébastien
      • Briancon Serge
      • Blacher Jacques
      • Hercberg Serge
      Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo-controlled trial.
      Almost all clinical studies for stroke prevention by B12 to date were conducted with cyanocobalamin. Dr. Spence has argued that the use of cyanocobalamin in individuals with renal impairment may have obscured the benefit of B vitamins in stroke prevention in earlier studies,
      • Spence J.D.
      • Yi Q.
      • Hankey G.J.
      B vitamins in stroke prevention: time to reconsider.
      ,
      • Spence J.D.
      • Hankey G.J.
      Problem in the recent American heart association guideline on secondary stroke prevention: B vitamins to lower homocysteine do prevent stroke.
      ,
      • Spence J.D.
      • Bang H.
      • Chambless L.E.
      • Stampfer M.J.
      Vitamin intervention for stroke prevention trial: an efficacy analysis.
      since it possible that increased cyanocobalamin leads to harmful accumulation of cyanide and thiocyanate in patients with impaired renal function.
      • Koyama K.
      • Yoshida A.
      • Takeda A.
      • Morozumi K.
      • Fujinami T.
      • Tanaka N.
      Abnormal cyanide metabolism in uraemic patients.

      Linked Article

      • B vitamins for NASH: Use methylcobalamin, not cyanocobalamin
        Journal of HepatologyVol. 78Issue 1
        • Preview
          Tripathi et al.1 have elegantly shown how hyperhomocysteinemia aggravates non-alcoholic steatohepatitis (NASH). Their finding that treatment with folate and B12 reduced inflammation and improved hepatic histology suggests that folate and B12 will be important therapies for this condition. However, it is crucial to recognize that the form of B12 used should be methylcobalamin or hydroxycobalamin, not cyanocobalamin, particularly in patients with impaired kidney function, including the elderly.
        • Full-Text
        • PDF
      • Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation
        Journal of HepatologyVol. 77Issue 5
        • Preview
          Several recent clinical studies have shown that serum homocysteine (Hcy) levels are positively correlated, while vitamin B12 (B12) and folate levels are negative correlated, with non-alcoholic steatohepatitis (NASH) severity. However, it is not known whether hyperhomocysteinemia (HHcy) plays a pathogenic role in NASH.
        • Full-Text
        • PDF
        Open Access
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Spence JD, B vitamins for NASH: use methylcobalamin, not cyanocobalamin, J Hepatol2023;78:e34–e35 https://dx.doi.org/10.1016/j.jhep.2022.08.019

        • Spence J.D.
        • Yi Q.
        • Hankey G.J.
        B vitamins in stroke prevention: time to reconsider.
        Lancet Neurol. 2017 Sep; 16: 750-760https://doi.org/10.1016/S1474-4422(17)30180-1
        • Spence J.D.
        • Hankey G.J.
        Problem in the recent American heart association guideline on secondary stroke prevention: B vitamins to lower homocysteine do prevent stroke.
        Stroke. 2022; 53: 2702-2708
        • Saposnik Gustavo
        The role of vitamin B in stroke prevention. A journey from observational studies to clinical trials and critique of the VITAmins to prevent stroke (vitatops).
        Stroke. 2011; 42: 838-842
        • Spence J.D.
        • Bang H.
        • Chambless L.E.
        • Stampfer M.J.
        Vitamin intervention for stroke prevention trial: an efficacy analysis.
        Stroke. 2005; 36: 2404-2409
        • Xu X.
        • Qin X.
        • Li Y.
        • Sun D.
        • Wang J.
        • Liang M.
        • et al.
        Efficacy of folic acid therapy on the progression of chronic kidney disease: the renal sub study of the China stroke primary prevention trial.
        JAMA Intern Med. 2016; 176: 1443-1450
        • Galan Pilar
        • Kesse-Guyot Emmanuelle
        • Czernichow Sébastien
        • Briancon Serge
        • Blacher Jacques
        • Hercberg Serge
        Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo-controlled trial.
        BMJ. 2010; 341: c6273
        • Koyama K.
        • Yoshida A.
        • Takeda A.
        • Morozumi K.
        • Fujinami T.
        • Tanaka N.
        Abnormal cyanide metabolism in uraemic patients.
        Nephrol Dial Transpl. 1997; 12: 1622-1628
        • Talari Hamid Reza
        • Molaqanbari Mohamad Reza
        • Mokfi Milad
        • Taghizadeh Mohsen
        • Bahmani Fereshteh
        • Hossein Tabatabaei Seyed Mohammad
        • et al.
        The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.
        Scientific Rep. 2022; 1214047